These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39284628)

  • 1. Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.
    Guha M; Thibault S; Pham S; Bernales S; Pai R; Herrera FJ; Johnson TR; Vitsky A; Fernando T; Finkelstein M
    J Pharmacol Exp Ther; 2024 Oct; 391(2):335-345. PubMed ID: 39284628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats.
    Rak GD; White MR; Augustine-Rauch K; Newsome C; Graziano MJ; Schulze GE
    J Appl Toxicol; 2020 Jul; 40(7):931-946. PubMed ID: 32061184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics-based approach for efficacious human dose projection of BMS-986260, a small molecule transforming growth factor beta receptor 1 inhibitor.
    Parrish KE; Swanson J; Cheng L; Luk E; Stetsko P; Smalley J; Shu YZ; Huang J; Pabalan JG; Sun Y; Zvyaga T; Cvijic ME; Burke J; Borzilleri R; Murtaza A; Augustine K; Yang Z
    Biopharm Drug Dispos; 2021 Apr; 42(4):137-149. PubMed ID: 33354831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.
    Yap TA; Choudhury AD; Hamilton E; Rosen LS; Stratton KL; Gordon MS; Schaer D; Liu L; Zhang L; Mittapalli RK; Zhong W; Soman N; Tolcher AW
    ESMO Open; 2024 Sep; 9(9):103653. PubMed ID: 39214047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
    Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
    Patyna S; Arrigoni C; Terron A; Kim TW; Heward JK; Vonderfecht SL; Denlinger R; Turnquist SE; Evering W
    Toxicol Pathol; 2008 Dec; 36(7):905-16. PubMed ID: 18981453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation.
    Zhong WZ; Zhan J; Kang P; Yamazaki S
    Curr Drug Metab; 2010 May; 11(4):296-306. PubMed ID: 20446906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
    de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
    J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition.
    Maher JM; Zhang R; Palanisamy G; Perkins K; Liu L; Brassil P; McNamara A; Lo A; Hughes AD; Kanodia J; Kulyk S; Nikula KJ; Dengler HS; Scandurra A; Lua I; Harstad E
    Toxicol Appl Pharmacol; 2022 Mar; 438():115905. PubMed ID: 35122773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
    Doi T; Lee KH; Kim TM; Ohtsu A; Kim TY; Ikeda M; Yoh K; Gallo Stampino C; Hirohashi T; Suzuki A; Fujii Y; Andrew Williams J; Bang YJ
    Cancer Med; 2016 Jul; 5(7):1454-63. PubMed ID: 27075560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
    Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
    Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.